Immuneering Corporation (IMRX)

Immuneering Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	59.41	72.64	74.89	37.09	13.78
Short-Term Investments	26.26	32.89	74.31	0	0
Cash & Cash Equivalents	85.67	105.52	149.2	37.09	13.78
Cash Growth	-18.82%	-29.27%	302.26%	169.12%	-
Receivables	0	0.01	0.25	0.5	0.21
Other Current Assets	3.42	3.21	2.89	0.14	0.07
Total Current Assets	89.08	108.75	152.33	37.73	14.06
Property, Plant & Equipment	5.4	5.78	6.13	0.68	0.04
Long-Term Investments	0	0	1	0	0
Goodwill and Intangibles	7.07	7.1	7.14	0	0
Other Long-Term Assets	1.03	0.74	0.1	0.01	0
Total Long-Term Assets	13.5	13.62	14.37	0.69	0.04
Total Assets	102.58	122.37	166.7	38.42	14.1
Accounts Payable	2.11	3.15	1.39	1.48	0.29
Current Debt	0.3	0.38	0.27	0.08	0
Other Current Liabilities	5.43	4.52	3.97	0.7	0.21
Total Current Liabilities	7.85	8.05	5.63	2.26	0.51
Long-Term Debt	4.16	4.46	5.09	0.54	0
Other Long-Term Liabilities	0	0	0	0	3.51
Total Long-Term Liabilities	4.16	4.46	5.09	0.54	3.51
Total Liabilities	12.01	12.52	10.72	2.8	4.02
Total Debt	4.46	4.84	5.36	0.62	0
Debt Growth	-7.82%	-9.75%	763.80%	-	-
Retained Earnings	-163.26	-109.79	-59.27	-25.74	-8.7
Comprehensive Income	-0	-0.03	-0.05	0	0
Shareholders' Equity	90.58	109.85	155.98	-22.48	-6.53
Net Cash / Debt	81.2	100.68	143.83	36.47	13.78
Net Cash / Debt Growth	-19.35%	-30.00%	294.40%	164.61%	-
Net Cash Per Share	2.86	3.82	10.57	7.37	3.90
Working Capital	81.24	100.69	146.7	35.48	13.56
Book Value Per Share	3.19	4.16	11.46	-4.54	-1.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).